Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
Over 340B Discounts on Orphan Drugs
10/3/2013 6:55:04 AM
Once again, the 340B Drug Pricing Program is at the center of a controversy. The latest flap involves discounts that the US Health Resources and Services Administration established for a select group of hospitals in order for them to obtain orphan drugs, which are medications that were approved by the FDA to treat rare diseases. An HRSA rule governing orphan drug discounts went into effect this week. In response, the PhRMA trade group has filed a lawsuit against HRSA and accused the agency of erroneously interpreting a provision of the Affordable Care Act that defines the extent of the discounts to be made available for orphan drugs.
Help employers find you! Check out all the
post your resume
(CVD) Hosts Governor
Eli Lilly and Company
(LLY) to Highlight Economic and Health Impact of Clinical Trial Research in Indiana
U.S. Court Lifts Ban on Competitor to
PDMA Alliance Sharing Conference
by Leading Workshops and Moderating Discussion With
Sues Filmmaker for Insider Trading Ahead of
Millennium Pharmaceuticals, Inc. (South San Francisco, California)
Robert J. Hugin
Ian C. Read
Kenneth C. Frazier
Assume New Posts
Traversa Therapeutics, Inc.
CEO Arrested in Shooting Spree
Orexigen Therapeutics, Inc.
Board of Directors
(NVS) to Investigate Bribery Claims at
(ACL) Unit in China
Medidata Solutions, Inc.
’ Extensive Real-world Cost Databases for Clinical Trial Analysis
Gan & Lee Pharmaceuticals
Sino Biopharmaceuticals Ltd.
(SBMFF) Get Caught Up in Corruption Allegations
comments powered by Disqus.
comments powered by
Biotech/Pharma - Legal